These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 26494964)

  • 61. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
    Patel YA; Imperial JC; Muir AJ; Anstee QM; DeBrota D; Dimick-Santos L; Filozof C; Mehta R; Sanyal AJ; Schabel E; Neuschwander-Tetri BA; Miller V;
    Gastroenterology; 2017 Sep; 153(3):621-625.e7. PubMed ID: 28757264
    [No Abstract]   [Full Text] [Related]  

  • 62. Genome-based nutrition: an intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis.
    Roman S; Ojeda-Granados C; Ramos-Lopez O; Panduro A
    World J Gastroenterol; 2015 Mar; 21(12):3449-61. PubMed ID: 25834309
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospects of evolution-based artificial intelligence models in genome-wide studies to stratify genetic risk variants in nonalcoholic fatty liver disease.
    Huang H; Awuah WA; Garg T; Ng JC; Mehta A; Ramamoorthy K; Kalmanovich J; Hasan MM
    Ann Med Surg (Lond); 2023 Jun; 85(6):2743-2748. PubMed ID: 37363524
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetics Meets Therapy? Exome-wide Association Study Reveals a Loss-of-Function Variant in 17-Beta-Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression.
    Sookoian S; Arrese M; Pirola CJ
    Hepatology; 2019 Feb; 69(2):907-910. PubMed ID: 30102780
    [No Abstract]   [Full Text] [Related]  

  • 65. Physical Activity Intensity, Genetic Predisposition, and Risk of Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study.
    Lv Y; Ding D; Luo M; Tan X; Xia Y; Chen L
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3444-3447.e2. PubMed ID: 36736971
    [No Abstract]   [Full Text] [Related]  

  • 66. Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories.
    Kantartzis K; Stefan N
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972374
    [No Abstract]   [Full Text] [Related]  

  • 67. Periostin on the road to nonalcoholic fatty liver disease.
    Polyzos SA; Anastasilakis AD
    Endocrine; 2016 Jan; 51(1):4-6. PubMed ID: 26585566
    [No Abstract]   [Full Text] [Related]  

  • 68. Challenges and opportunities in stroke genetics.
    Malik R; Dichgans M
    Cardiovasc Res; 2018 Jul; 114(9):1226-1240. PubMed ID: 29554300
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical utility of polygenic risk scores for predicting NAFLD disorders.
    Dessein A
    J Hepatol; 2021 Apr; 74(4):769-770. PubMed ID: 33653592
    [No Abstract]   [Full Text] [Related]  

  • 70. At the end of the beginning. Foreword.
    Karlsen TH; Lazaridis KN
    Semin Liver Dis; 2011 May; 31(2):111-3. PubMed ID: 21538278
    [No Abstract]   [Full Text] [Related]  

  • 71. Mendelian randomization elucidates links between nonalcoholic fatty liver disease and stroke.
    Parikh NS
    Eur J Neurol; 2022 May; 29(5):1291-1292. PubMed ID: 35263808
    [No Abstract]   [Full Text] [Related]  

  • 72. Identifying the Genetics Underlying Nonalcoholic Fatty Liver Disease: A Quest That is Far From Over.
    Koot BGP; Jansen PR
    J Pediatr Gastroenterol Nutr; 2021 Aug; 73(2):139-140. PubMed ID: 34402808
    [No Abstract]   [Full Text] [Related]  

  • 73. Sweating it out: How physical activity can combat high genetic risk for nonalcoholic fatty liver disease.
    Stine JG; Romeo S
    Liver Int; 2023 Aug; 43(8):1623-1625. PubMed ID: 37452506
    [No Abstract]   [Full Text] [Related]  

  • 74. Genetic correlation, yet no causal association exists between nonalcoholic fatty liver disease and depression.
    Zhang X; Wu P; Lin Y
    J Affect Disord; 2022 Nov; 316():243-244. PubMed ID: 35987304
    [No Abstract]   [Full Text] [Related]  

  • 75. Complexity, Genetic Causation, and Hereditarianism.
    Roseman CC
    Hum Biol; 2018 Nov; 90(4):241-250. PubMed ID: 31714692
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Precision medicine in nonalcoholic fatty liver disease.
    Lonardo A
    J Gastroenterol Hepatol; 2022 Jul; 37(7):1175-1178. PubMed ID: 35801994
    [No Abstract]   [Full Text] [Related]  

  • 77. Genome-Wide Association Studies and Liver Disease.
    Speliotes EK
    Semin Liver Dis; 2015 Nov; 35(4):355-60. PubMed ID: 26676811
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dietary approach in the treatment of nonalcoholic fatty liver disease.
    Ferolla SM; Silva LC; Ferrari Mde L; da Cunha AS; Martins Fdos S; Couto CA; Ferrari TC
    World J Hepatol; 2015 Oct; 7(24):2522-34. PubMed ID: 26523205
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population.
    Zegers D; Verrijken A; Beckers S; Francque S; Van Camp JK; Aerts E; Ruppert M; Hubens G; Michielsen P; Van Hul W; Van Gaal LF
    Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):333-339. PubMed ID: 26500201
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The invasion of fatty liver disease in liver transplantation.
    Darwish Murad S; Metselaar HJ
    Transpl Int; 2016 Apr; 29(4):416-7. PubMed ID: 26497817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.